daytrading jan 8 afternoon, page-7

I think it's fair to say HC does have a certain ingrained "mood" of positivism, which is why the more openly sceptical voices like qqqqqqqqq stand out.

Personally, I'm all in favour of scepticism.

Take RMX for example: with 6 months to go on RMXO option strike at 0.015, there hasn't been a lot of interest at 0.002, suggesting the smart money doesn't think RMX is going to improve much - if at all - on it's current spike of 0.013 or so.

So mumbles about RMX being a P & D special seem perfectly valid to me - I don't know that it's right, just that it's valid.

Meanwhile, in flakey biotech land:

AHZ - I think I should stop calling Admedus a flakey biotech. It's starting to look like a proper biotech.

NEU - out of fashion recently, but hasn't fallen off much and has found a base at 0.11c. No doubt it will run ("schlactobunta"?) if it can come up with any positive news.

BLT - same as above, but I think the science is more 'out there' and chancier. Not that I know about genetic science.

CDY - a crowd favourite ... when there's a crowd. I picked up a few at 0.031 simply because I think it's got one more pump in it. I just think that sooner or later there'll be one last pump and it'll die it's natural death.

GTG - biotech's soap opera. You'd want to look into the corporate/shareholder history to make sense of this one. It's messy, bitchy and downright nuts. However, this morning's announcement indicates that they may actually be able to market their breast-cancer detection kit successfully, so I bought back in. For a biotech with revenue in the genetic/breast-cancer space, surely it's got a future ... oh wait - this is GTG we're talking about. Nothing sensible applies.

Regards,

P